Teva Pharmaceutical Industries (TEVA) Competitors $13.58 +0.12 (+0.89%) As of 04/14/2025 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TEVA vs. TAK, ARGX, ONC, BNTX, ITCI, SMMT, GMAB, RDY, MRNA, and VTRSShould you be buying Teva Pharmaceutical Industries stock or one of its competitors? The main competitors of Teva Pharmaceutical Industries include Takeda Pharmaceutical (TAK), argenx (ARGX), Beigene (ONC), BioNTech (BNTX), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. Teva Pharmaceutical Industries vs. Takeda Pharmaceutical argenx Beigene BioNTech Intra-Cellular Therapies Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Takeda Pharmaceutical (NYSE:TAK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, community ranking, media sentiment, valuation, profitability and analyst recommendations. Does the media refer more to TAK or TEVA? In the previous week, Teva Pharmaceutical Industries had 14 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 21 mentions for Teva Pharmaceutical Industries and 7 mentions for Takeda Pharmaceutical. Teva Pharmaceutical Industries' average media sentiment score of 1.08 beat Takeda Pharmaceutical's score of 0.49 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 2 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Teva Pharmaceutical Industries 14 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in TAK or TEVA? Teva Pharmaceutical Industries received 1233 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 67.82% of users gave Teva Pharmaceutical Industries an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformTakeda PharmaceuticalOutperform Votes10157.06% Underperform Votes7642.94% Teva Pharmaceutical IndustriesOutperform Votes133467.82% Underperform Votes63332.18% Is TAK or TEVA a better dividend stock? Takeda Pharmaceutical pays an annual dividend of $0.53 per share and has a dividend yield of 3.7%. Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 7.4%. Takeda Pharmaceutical pays out 132.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Teva Pharmaceutical Industries pays out -69.7% of its earnings in the form of a dividend. Teva Pharmaceutical Industries is clearly the better dividend stock, given its higher yield and lower payout ratio. Is TAK or TEVA more profitable? Takeda Pharmaceutical has a net margin of 4.53% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical4.53% 9.39% 4.53% Teva Pharmaceutical Industries -9.91%42.46%6.65% Do analysts rate TAK or TEVA? Teva Pharmaceutical Industries has a consensus target price of $23.43, suggesting a potential upside of 72.52%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Do institutionals & insiders believe in TAK or TEVA? 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation & earnings, TAK or TEVA? Takeda Pharmaceutical has higher revenue and earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$4.58T0.01$994.06M$0.4035.73Teva Pharmaceutical Industries$16.54B0.93-$1.64B-$1.45-9.37 Which has more risk and volatility, TAK or TEVA? Takeda Pharmaceutical has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. SummaryTeva Pharmaceutical Industries beats Takeda Pharmaceutical on 14 of the 20 factors compared between the two stocks. Remove Ads Get Teva Pharmaceutical Industries News Delivered to You Automatically Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TEVA vs. The Competition Export to ExcelMetricTeva Pharmaceutical IndustriesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$15.40B$6.35B$5.35B$18.51BDividend YieldN/A3.23%5.11%4.25%P/E Ratio-9.376.7721.6831.06Price / Sales0.93228.59376.3326.47Price / Cash5.0565.6738.1517.54Price / Book2.865.886.444.29Net Income-$1.64B$141.32M$3.20B$1.02B7 Day Performance0.33%8.48%9.01%6.72%1 Month Performance-17.07%-12.84%-6.09%-6.79%1 Year Performance2.65%-12.40%10.72%1.22% Teva Pharmaceutical Industries Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TEVATeva Pharmaceutical Industries3.0106 of 5 stars$13.58+0.9%$23.43+72.5%+2.1%$15.40B$16.54B-9.3736,800Analyst DowngradeOptions VolumePositive NewsTAKTakeda Pharmaceutical2.3626 of 5 stars$14.34-2.6%N/A+6.9%$45.62B$4.58T35.8547,300Gap UpHigh Trading VolumeARGXargenx3.1269 of 5 stars$552.88-0.4%$687.00+24.3%+60.4%$33.57B$2.19B-627.77650ONCBeigene2.2846 of 5 stars$221.60-7.1%$310.40+40.1%N/A$21.87B$3.81B-26.8910,600Gap DownBNTXBioNTech2.5187 of 5 stars$85.59-2.8%$143.44+67.6%+18.3%$20.48B$2.75B-40.643,080Gap DownITCIIntra-Cellular Therapies3.4982 of 5 stars$131.87flat$106.23-19.4%N/A$14.05B$680.50M-151.57560Analyst ForecastPositive NewsSMMTSummit Therapeutics2.6255 of 5 stars$17.19-1.0%$35.40+105.9%+613.0%$12.68B$700,000.00-61.39110Gap UpGMABGenmab A/S4.2212 of 5 stars$18.23-0.9%$41.33+126.7%-34.0%$12.06B$21.53B10.471,660Short Interest ↓Gap DownHigh Trading VolumeRDYDr. Reddy's Laboratories3.0786 of 5 stars$12.56+1.6%$17.00+35.4%-7.2%$10.48B$311.31B20.0024,800Positive NewsMRNAModerna4.3313 of 5 stars$25.25+0.5%$59.00+133.7%-74.5%$9.77B$3.20B-2.723,900Positive NewsGap UpVTRSViatris2.9578 of 5 stars$7.61-0.1%$10.50+37.9%-32.7%$9.10B$14.74B-10.3037,000 Remove Ads Related Companies and Tools Related Companies TAK Alternatives ARGX Alternatives ONC Alternatives BNTX Alternatives ITCI Alternatives SMMT Alternatives GMAB Alternatives RDY Alternatives MRNA Alternatives VTRS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:TEVA) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
